Seres Therapeutics, Inc. Research and Development Expense
Seres Therapeutics, Inc. (MCRB) reported Research and Development Expense of $9.14 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-05
- Seres Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $9.14M, a 29.35% decline year-over-year.
- Seres Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $13.20M, a 11.62% increase year-over-year.
- Seres Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $11.68M, a 9.01% decline year-over-year.
- Seres Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $12.62M, a 23.35% decline year-over-year.
- Seres Therapeutics, Inc. research and development expense for fiscal 2025 was $49.06M, a 24.06% decline from fiscal 2024.
- Seres Therapeutics, Inc. research and development expense for fiscal 2024 was $64.60M, a 45.07% decline from fiscal 2023.
- Seres Therapeutics, Inc. research and development expense for fiscal 2023 was $117.60M, a 7.25% increase from fiscal 2022.
- Seres Therapeutics, Inc. research and development expense for fiscal 2022 was $109.65M, a 22.72% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $9.14M 10-Q · filed 2026-08-05 | $22.34M 10-Q · filed 2026-08-05 | $34.02M derived: sum of 3 quarters · filed 2026-08-05 | $46.64M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $13.20M 10-Q · filed 2026-05-05 | $24.88M derived: sum of 2 quarters · filed 2026-05-05 | $37.49M derived: sum of 3 quarters · filed 2026-05-05 | $50.43M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $11.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $24.30M derived: sum of 2 quarters · filed 2026-03-12 | $37.24M derived: sum of 3 quarters · filed 2026-08-05 | $49.06M 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | $12.62M 10-Q · filed 2025-11-05 | $25.55M derived: sum of 2 quarters · filed 2026-08-05 | $37.38M 10-Q · filed 2025-11-05 | $50.22M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $12.94M 10-Q · filed 2026-08-05 | $24.76M 10-Q · filed 2026-08-05 | $37.60M derived: sum of 3 quarters · filed 2026-08-05 | $54.06M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $11.82M 10-Q · filed 2026-05-05 | $24.66M derived: sum of 2 quarters · filed 2026-05-05 | $41.12M derived: sum of 3 quarters · filed 2026-05-05 | $56.93M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $12.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $29.30M derived: sum of 2 quarters · filed 2026-03-12 | $45.11M derived: sum of 3 quarters · filed 2026-03-12 | $64.60M 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | $16.46M 10-Q · filed 2025-11-05 | $32.27M derived: sum of 2 quarters · filed 2025-11-05 | $51.76M 10-Q · filed 2025-11-05 | $74.80M derived: sum of 4 quarters · filed 2026-03-12 | ||||
| 2024-06-30 | $15.81M 10-Q · filed 2025-08-06 | $17.88M 10-Q · filed 2024-08-13 | $35.30M 10-Q · filed 2025-08-06 | $39.58M 10-Q · filed 2024-08-13 | $58.34M derived: sum of 3 quarters · filed 2026-03-12 | $83.50M derived: sum of 4 quarters · filed 2026-03-12 | ||
| 2024-03-31 | $19.49M 10-Q · filed 2025-05-07 | $21.70M 10-Q · filed 2024-05-08 | $42.54M derived: sum of 2 quarters · filed 2026-03-12 | $67.69M derived: sum of 3 quarters · filed 2026-03-12 | $114.48M derived: sum of 4 quarters · filed 2026-03-12 | |||
| 2023-12-31 | $23.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $48.20M derived: sum of 2 quarters · filed 2026-03-12 | $94.99M derived: sum of 3 quarters · filed 2026-03-12 | $117.60M 10-K · filed 2026-03-12 | $145.86M 10-K · filed 2024-03-05 | |||
| 2023-09-30 | $25.15M 10-Q · filed 2024-11-13 | $28.25M 10-Q · filed 2023-11-02 | $71.95M derived: sum of 2 quarters · filed 2024-11-13 | $94.55M 10-Q · filed 2024-11-13 | $119.01M 10-Q · filed 2023-11-02 | $98.87M derived: sum of 4 quarters · filed 2025-03-13 | ||
| 2023-06-30 | $46.79M 10-Q · filed 2024-08-13 | $90.76M 10-Q · filed 2024-08-13 | $73.71M derived: sum of 3 quarters · filed 2025-03-13 | $116.83M derived: sum of 4 quarters · filed 2025-03-13 | ||||
| 2023-03-31 | $43.97M 10-Q · filed 2024-05-08 | $26.92M derived: sum of 2 quarters · filed 2025-03-13 | $70.04M derived: sum of 3 quarters · filed 2025-03-13 | $113.97M derived: sum of 4 quarters · filed 2025-03-13 | ||||
| 2022-12-31 | -$17.05M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $26.07M derived: sum of 2 quarters · filed 2025-03-13 | $70.00M derived: sum of 3 quarters · filed 2025-03-13 | $109.65M 10-K · filed 2025-03-13 | $172.92M 10-K · filed 2023-03-07 | |||
| 2022-09-30 | $43.12M 10-Q · filed 2023-11-02 | $87.05M derived: sum of 2 quarters · filed 2023-11-02 | $126.70M 10-Q · filed 2023-11-02 | $163.45M derived: sum of 4 quarters · filed 2024-03-05 | ||||
| 2022-06-30 | $43.94M 10-Q · filed 2023-08-08 | $83.58M 10-Q · filed 2023-08-08 | $120.34M derived: sum of 3 quarters · filed 2024-03-05 | $160.22M derived: sum of 4 quarters · filed 2024-03-05 | ||||
| 2022-03-31 | $39.65M 10-Q · filed 2023-05-09 | $76.40M derived: sum of 2 quarters · filed 2024-03-05 | $116.28M derived: sum of 3 quarters · filed 2024-03-05 | $152.24M derived: sum of 4 quarters · filed 2024-03-05 | ||||
| 2021-12-31 | $36.75M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $76.63M derived: sum of 2 quarters · filed 2024-03-05 | $112.59M derived: sum of 3 quarters · filed 2024-03-05 | $141.89M 10-K · filed 2024-03-05 | ||||
| 2021-09-30 | $39.88M 10-Q · filed 2022-11-02 | $75.84M derived: sum of 2 quarters · filed 2022-11-02 | $105.14M 10-Q · filed 2022-11-02 | $130.01M derived: sum of 4 quarters · filed 2023-03-07 | ||||
| 2021-06-30 | $35.95M 10-Q · filed 2022-08-03 | $65.26M 10-Q · filed 2022-08-03 | $90.12M derived: sum of 3 quarters · filed 2023-03-07 | $113.98M derived: sum of 4 quarters · filed 2023-03-07 | ||||
| 2021-03-31 | $29.30M 10-Q · filed 2022-05-04 | $54.17M derived: sum of 2 quarters · filed 2023-03-07 | $78.03M derived: sum of 3 quarters · filed 2023-03-07 | $98.13M derived: sum of 4 quarters · filed 2023-03-07 | ||||
| 2020-12-31 | $24.87M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $48.73M derived: sum of 2 quarters · filed 2023-03-07 | $68.83M derived: sum of 3 quarters · filed 2023-03-07 | $90.57M 10-K · filed 2023-03-07 | ||||
| 2020-09-30 | $23.86M 10-Q · filed 2021-11-10 | $43.96M derived: sum of 2 quarters · filed 2021-11-10 | $65.70M 10-Q · filed 2021-11-10 | $86.73M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2020-06-30 | $20.10M 10-Q · filed 2021-08-03 | $41.84M 10-Q · filed 2021-08-03 | $62.87M derived: sum of 3 quarters · filed 2022-03-01 | $81.19M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2020-03-31 | $21.74M 10-Q · filed 2021-05-04 | $42.77M derived: sum of 2 quarters · filed 2022-03-01 | $61.09M derived: sum of 3 quarters · filed 2022-03-01 | $79.00M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2019-12-31 | $21.03M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $39.35M derived: sum of 2 quarters · filed 2022-03-01 | $57.25M derived: sum of 3 quarters · filed 2022-03-01 | $80.14M 10-K · filed 2022-03-01 | ||||
| 2019-09-30 | $18.32M 10-Q · filed 2020-11-09 | $36.22M derived: sum of 2 quarters · filed 2020-11-09 | $59.11M 10-Q · filed 2020-11-09 | $83.88M derived: sum of 4 quarters · filed 2021-03-02 | ||||
| 2019-06-30 | $17.91M 10-Q · filed 2020-07-28 | $40.79M 10-Q · filed 2020-07-28 | $65.56M derived: sum of 3 quarters · filed 2021-03-02 | $89.23M derived: sum of 4 quarters · filed 2021-03-02 | ||||
| 2019-03-31 | $22.89M 10-Q · filed 2020-05-07 | $47.65M derived: sum of 2 quarters · filed 2021-03-02 | $71.33M derived: sum of 3 quarters · filed 2021-03-02 | $95.38M derived: sum of 4 quarters · filed 2021-03-02 | ||||
| 2018-12-31 | $24.77M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-02 | $48.44M derived: sum of 2 quarters · filed 2021-03-02 | $72.50M derived: sum of 3 quarters · filed 2021-03-02 | $95.95M 10-K · filed 2021-03-02 | ||||
| 2018-09-30 | $23.68M 10-Q · filed 2019-11-05 | $47.73M derived: sum of 2 quarters · filed 2019-11-05 | $71.19M 10-Q · filed 2019-11-05 | $95.23M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2018-06-30 | $24.05M 10-Q · filed 2019-08-06 | $47.51M 10-Q · filed 2019-08-06 | $71.56M derived: sum of 3 quarters · filed 2020-03-02 | $93.77M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2018-03-31 | $23.46M 10-Q · filed 2019-05-02 | $47.50M derived: sum of 2 quarters · filed 2020-03-02 | $69.71M derived: sum of 3 quarters · filed 2020-03-02 | $92.77M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2017-12-31 | $24.04M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $46.25M derived: sum of 2 quarters · filed 2020-03-02 | $69.31M derived: sum of 3 quarters · filed 2020-03-02 | $89.45M 10-K · filed 2020-03-02 | ||||
| 2017-09-30 | $22.21M 10-Q · filed 2018-11-08 | $45.27M derived: sum of 2 quarters · filed 2018-11-08 | $65.41M 10-Q · filed 2018-11-08 | $85.67M derived: sum of 4 quarters · filed 2019-03-06 | ||||
| 2017-06-30 | $23.06M 10-Q · filed 2018-08-02 | $43.20M 10-Q · filed 2018-08-02 | $63.46M derived: sum of 3 quarters · filed 2019-03-06 | $87.60M derived: sum of 4 quarters · filed 2019-03-06 | ||||
| 2017-03-31 | $20.14M 10-Q · filed 2018-05-09 | $40.40M derived: sum of 2 quarters · filed 2019-03-06 | $64.54M derived: sum of 3 quarters · filed 2019-03-06 | $86.72M derived: sum of 4 quarters · filed 2019-03-06 | ||||
| 2016-12-31 | $20.26M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06 | $44.40M derived: sum of 2 quarters · filed 2019-03-06 | $66.57M derived: sum of 3 quarters · filed 2019-03-06 | $81.99M 10-K · filed 2019-03-06 | ||||
| 2016-09-30 | $24.14M 10-Q · filed 2017-11-08 | $46.32M derived: sum of 2 quarters · filed 2017-11-08 | $61.73M 10-Q · filed 2017-11-08 | $75.63M derived: sum of 4 quarters · filed 2018-03-08 | ||||
| 2016-06-30 | $22.17M 10-Q · filed 2017-08-03 | $37.59M 10-Q · filed 2017-08-03 | $51.49M derived: sum of 3 quarters · filed 2018-03-08 | $61.34M derived: sum of 4 quarters · filed 2018-03-08 | ||||
| 2016-03-31 | $15.42M 10-Q · filed 2017-05-04 | $29.32M derived: sum of 2 quarters · filed 2018-03-08 | $39.17M derived: sum of 3 quarters · filed 2018-03-08 | $47.95M derived: sum of 4 quarters · filed 2018-03-08 | ||||
| 2015-12-31 | $13.90M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $23.75M derived: sum of 2 quarters · filed 2018-03-08 | $32.53M derived: sum of 3 quarters · filed 2018-03-08 | $38.09M 10-K · filed 2018-03-08 | ||||
| 2015-09-30 | $9.85M 10-Q · filed 2016-11-10 | $18.63M derived: sum of 2 quarters · filed 2016-11-10 | $24.20M 10-Q · filed 2016-11-10 | $32.48M derived: sum of 4 quarters · filed 2017-03-16 | ||||
| 2015-06-30 | $8.78M 10-Q · filed 2015-08-10 | $14.35M 10-Q · filed 2016-08-11 | $22.63M derived: sum of 3 quarters · filed 2017-03-16 | $25.09M derived: sum of 4 quarters · filed 2017-03-16 | ||||
| 2015-03-31 | $8.78M 10-Q · filed 2016-08-11 | $5.56M 10-Q · filed 2016-05-16 | $13.84M derived: sum of 2 quarters · filed 2017-03-16 | $16.31M derived: sum of 3 quarters · filed 2017-03-16 | $18.47M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2014-12-31 | $5.06M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $7.53M derived: sum of 2 quarters · filed 2017-03-16 | $9.69M derived: sum of 3 quarters · filed 2017-03-16 | $10.72M 10-K · filed 2017-03-16 | ||||
| 2014-09-30 | $2.47M 10-Q · filed 2015-11-12 | $4.63M derived: sum of 2 quarters · filed 2015-11-12 | $5.66M 10-Q · filed 2015-11-12 | |||||
| 2014-06-30 | $2.16M 10-Q · filed 2015-08-10 | $3.19M 10-Q · filed 2015-08-10 | ||||||
| 2013-12-31 | $4.80M 10-K · filed 2016-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |